Johnson & Johnson (NYSE:JNJ) Shares Sold by Falcon Wealth Planning

Falcon Wealth Planning lowered its stake in Johnson & Johnson (NYSE:JNJ) by 4.7% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 2,694 shares of the company’s stock after selling 132 shares during the period. Falcon Wealth Planning’s holdings in Johnson & Johnson were worth $394,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Pathway Financial Advisors LLC lifted its stake in Johnson & Johnson by 4.3% during the fourth quarter. Pathway Financial Advisors LLC now owns 5,438 shares of the company’s stock worth $852,000 after purchasing an additional 226 shares during the last quarter. Daiwa Securities Group Inc. grew its position in shares of Johnson & Johnson by 5.5% during the 4th quarter. Daiwa Securities Group Inc. now owns 297,850 shares of the company’s stock valued at $46,685,000 after buying an additional 15,490 shares during the last quarter. Drive Wealth Management LLC raised its stake in Johnson & Johnson by 4.5% during the first quarter. Drive Wealth Management LLC now owns 9,625 shares of the company’s stock worth $1,523,000 after acquiring an additional 414 shares during the period. Vestmark Advisory Solutions Inc. lifted its holdings in Johnson & Johnson by 12.7% in the fourth quarter. Vestmark Advisory Solutions Inc. now owns 19,587 shares of the company’s stock worth $3,070,000 after acquiring an additional 2,201 shares during the last quarter. Finally, California Public Employees Retirement System boosted its stake in Johnson & Johnson by 4.9% in the fourth quarter. California Public Employees Retirement System now owns 10,620,264 shares of the company’s stock valued at $1,664,620,000 after acquiring an additional 498,647 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Morgan Stanley raised their price target on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a report on Thursday, July 18th. Royal Bank of Canada reissued an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a report on Tuesday, July 30th. TD Securities reduced their price target on Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Finally, StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 8th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded up $0.62 on Wednesday, reaching $159.01. 2,549,110 shares of the company traded hands, compared to its average volume of 7,340,324. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The stock has a market capitalization of $382.69 billion, a PE ratio of 9.89, a P/E/G ratio of 2.63 and a beta of 0.52. The company’s 50 day moving average is $151.63 and its 200-day moving average is $153.06. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.39.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. Johnson & Johnson’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter last year, the company posted $2.80 EPS. As a group, analysts anticipate that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.12%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.